(E)-4-(dimethylamino)-1-(4-[(1R)-1-phenylethyl]amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-2-buten-1-one | 1130153-26-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: (E)-4-(dimethylamino)-1-(4-[(1R)-1-phenylethyl]amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-2-buten-1-one
• 英文别名: 7-[(2E)-4-(dimethylamino)but-2-enoyl]-N-[(1R)-1-phenylethyl]-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4-amine；(E)-4-(dimethylamino)-1-[3-[[(1R)-1-phenylethyl]amino]-8-thia-4,6,11-triazatricyclo[7.4.0.02,7]trideca-1(9),2,4,6-tetraen-11-yl]but-2-en-1-one
• CAS: 1130153-26-2
• 化学式: C₂₃H₂₇N₅OS
• 分子量: 421.566
• InChiKey: BVGZQNBERZRYJK-OJXHRBAXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  89.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  、 二甲胺 以 四氢呋喃 、 水 为溶剂， 反应 2.0h， 生成 (E)-4-(dimethylamino)-1-(4-[(1R)-1-phenylethyl]amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-2-buten-1-one
  参考文献：
  名称：

  Design and Synthesis of Tetrahydropyridothieno[2,3-d]pyrimidine Scaffold Based Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors: The Role of Side Chain Chirality and Michael Acceptor Group for Maximal Potency

  摘要：

  HTS hit 7 was modified through hybrid design strategy to introduce a chiral side chain followed by introduction of Michael acceptor group to obtain potent EGFR kinase inhibitors 11 and 19. Both 11 and 19 showed over 3 orders of magnitude enhanced HCC827 antiproliferative activity compared to HTS hit 7 and also inhibited gefitinib-resistant double mutant (DM, T790M/L858R) EGFR kinase at nanomolar concentration. Moreover, treatment with 19 shrinked tumor in nude mice xenograft model.

  DOI：

  10.1021/jm100607r

文献信息

• [EN] SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS TRICYCLIQUES SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：BAYER HEALTHCARE AG

  公开号：WO2009033581A1

  公开（公告）日：2009-03-19

  This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.

  这项发明涉及新颖化合物及其制备方法，治疗疾病的方法，特别是癌症，包括给予这些化合物，以及制备用于治疗或预防疾病，特别是癌症的药物组合物的方法。
• Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors
  申请人：Hsieh Hsing-Pang

  公开号：US20100120805A1

  公开（公告）日：2010-05-13

  Fused bicyclic or tricyclic compounds of formula (I): wherein A, B, C, X, Y, m, and n are defined herein. Also disclosed are a method for inhibiting EGFR kinase activity and a method for treating cancer with these compounds.

  式(I)的融合双环或三环化合物： 其中A、B、C、X、Y、m和n在此处定义。还公开了一种抑制EGFR激酶活性的方法以及使用这些化合物治疗癌症的方法。
• Substituted tricyclic compounds and methods of use thereof
  申请人：Schirok Hartmut

  公开号：US08524722B2

  公开（公告）日：2013-09-03

  This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.

  本发明涉及新型化合物及其制备方法，涉及用于治疗疾病的方法，尤其是癌症，包括给予该化合物的方法，以及制备用于治疗或预防疾病，尤其是癌症的药物组合物的方法。
• SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Schirok Hartmut

  公开号：US20110021493A1

  公开（公告）日：2011-01-27

  This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.

  本发明涉及新型化合物及其制备方法，涉及使用该化合物治疗疾病的方法，特别是癌症，以及制备用于治疗或预防疾病，特别是癌症的药物组合物的方法。
• US8507502B2
  申请人：——

  公开号：US8507502B2

  公开（公告）日：2013-08-13